New Website Helps People Trying to Navigate Their PrEP Options
A team led by Shannon Weber, M.S.W., has developed PleasePrEPMe, an online PrEP provider search and chat service.
Featured
My Former Patient was Denied PEP at a Big Atlanta HIV Organization. Here's What I Did.
David Malebranche's former patient tried to get PEP at a major Atlanta HIV clinic and was initally denied. Though the situation has been made right, it's important to make sure this doesn't happen again.
New Study Will Test Safety of PrEP and Dapivirine Ring in Pregnancy
While the vaginal ring is still currently under FDA review, the new study will show whether it is safe and acceptable for people who are pregnant.
HIV Vaccine Trial Stopped Early, but Research Into Other Approaches Continues
HVTN 702 is but one of many vaccine trials underway, researchers note.
Barriers to Cisgender Women and HIV Prevention
Health care providers and educators need to acknowledge the impact of clinical bias and reframe sexual health education when it comes to tending to cisgender women's needs, Chase Alston writes.
One-Two Punch of Antibodies and Antiretrovirals Stops HIV Infection in Primate Infants
While it is too soon to tell, this research involving broadly neutralizing antibodies could point to new methods for preventing vertical transmission.
Common Antidepressant Reduces Meth Use and High-Risk Sexual Behavior for Gay and Bisexual Men and Transgender Women
Could this give hope to people struggling with crystal meth addiction?
How to Keep America's Blood Banks HIV-Free While Letting All Gay Men Donate
Even after a series of reforms in 2015, advocates say U.S. policy still discriminates and furthers HIV stigma. Anthony Santella, Dr.P.H., M.P.H., has a better idea.
Misleading Ads About PrEP Are Threatening Progress to End the HIV Epidemic. They Must Be Removed.
Pre-exposure prophylaxis (PrEP) is a vital part of ending HIV, but ads targeting people to join lawsuits are planting needless fears in patients, three leading HIV specialists write.
FDA Approves Descovy for PrEP, but Only for Cisgender Men and Transgender Women
The FDA approved the fixed-dose combination of emtricitabine and tenofovir alafenamide for PrEP, but advocates hope to see more research on the HIV prevention drug's efficacy for receptive vaginal sex for cisgender women and transgender men.
Washington, D.C. Youth Face Barriers to HIV Prevention and Sexual Health
Young people in the nation's capital are living in the middle of some of the worst structural and systemic inequalities in America. We should be helping them out.